Related Experiment Videos
Summary
Serum copper levels (SCL) are significantly higher in women with ovarian carcinoma compared to benign pelvic masses. A level of 150 micrograms/dl can distinguish between ovarian cancer and benign conditions, and also predict treatment response.
Area of Science:
- Gynecology
- Oncology
- Clinical Chemistry
Background:
- Pelvic masses require accurate diagnosis to differentiate between benign and malignant conditions.
- Ovarian carcinoma is a significant health concern, necessitating improved diagnostic markers.
- Serum copper levels (SCL) have been investigated as potential biomarkers.
Purpose of the Study:
- To evaluate serum copper levels as a diagnostic marker for ovarian carcinoma.
- To determine if SCL can differentiate ovarian cancer from benign pelvic lesions.
- To assess the utility of SCL in predicting response to chemotherapy in ovarian cancer patients.
Main Methods:
- Serum copper levels were measured in 40 women with pelvic masses before treatment.
- SCL were also assessed in ovarian carcinoma patients post-chemotherapy and pre-second-look operation.
- Statistical analysis was performed to compare SCL between groups.
Main Results:
- Patients with ovarian carcinoma exhibited significantly higher SCL than those with benign ovarian lesions.
- A serum copper level of 150 micrograms/dl effectively distinguished ovarian carcinoma from benign pelvic masses.
- The same threshold of 150 micrograms/dl differentiated between responders and non-responders to chemotherapy in ovarian cancer.
Conclusions:
- Serum copper levels show promise as a biomarker for ovarian carcinoma.
- SCL can aid in the differential diagnosis of pelvic masses.
- SCL may assist in monitoring treatment efficacy and predicting residual disease in ovarian cancer.